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One of the more important aspects for treatment of patients with inflammatory
bowel disease is the search for the identification of patient subgroups (1). This is
important for the management of acute and sub-acute episodes and for establishing
the long term prognosis. In particular, for those patients at risk of frequent relapses.
In spite of the introduction in the 1950’s of glucocorticosteroids for the treatment of
acute attacks which has decreased the mortality rate of the disease, not all patients
respond, not even to any of the most sophisticated biological therapies introduced
recently. The prevention of relapse and recurrence continues to be a challenge.
Thus, the question that the gastroenterologists need to respond is whether we have
good markers to identify patient’s subgroups and if not, how can we improve the de-
sign of our studies to achieve this goal?
Since there is overwhelming evidence that genetic factors play a role in the sus-
ceptibility to IBD (2-4) the study of genetic polymorphisms that are involved in the
regulation of inflammation, such as HLA and cytokine gene polymorphisms has
been the focus of attention. 
As stated in the article by the clinical investigators from Valencia in this issue of
the Revista Española de Enfermedades Digestivas (5), the working hypothesis to un-
derstand the pathogenesis of these diseases is that chronic inflammatory bowel di-
seases (IBD) occur as a result of a dysregulated immune response against an as yet
unknown factor in a genetically predisposed host. Due to the often observed linkage
disequilibrium, whereby alleles located in close proximity are not randomly asso-
ciated, but occur more frequently together than would be predicted by the individual
allele frequencies, one may assume that certain genes are not involved by themsel-
ves in disease pathogenesis. They are signalling the presence of other genes that do
play a role in determining the heterogeneity of the disease. From this point of view
the HLA system and serological markers of the dysregulation of the immune system
appear to be good candidates to study.
Another reason to investigate genetic and serological markers is the absence of
pathognomonic markers for Crohn's disease, ulcerative colitis and for the 10% of
cases of colitis that do not belong to either category. This has been recently done by
evaluating the value of anti-Saccharomyces cerevisiae antibodies (ASCA) and peri-
nuclear antineutrophil cytoplasmic antibodies (pANCA) in order to increase diag-
nostic accuracy in categorizing intermediate colitis (6).
It is very likely that both serological markers  and genetic factors which have
been described in different patient populations, identify subgroups of patients who
may not have been properly identified and defined. For example, IgG-pANCA, IgA-
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and IgC-ASCA, antibody against pancreas (PAB) were shown to be independently
associated with early age of onset of the disease, as well as fibrostenosing and in-
ternal penetrating disease behaviour. Higher pANCA levels were associated with
later age of onset of disease and ulcerative colitis-like behaviour. However, the sole
monitoring of pANCA, its specificity, and titre determination does not add to the in-
formation obtained with standard procedures. The combination of a positive ASCA
and a negative pANCA predicts Crohn’s disease in 80% of patients with indetermi-
nate colitis and the combination of ASCA-negative and pANCA-positive predicts ul-
cerative colitis in 63.6% of these patients. Interestingly, 48.5% of patients do not
show antibodies against ASCA or pANCA. Most of these patients remain diagnosed
with indeterminate colitis during their further clinical course; possibly they form a
distinct clinical-serological subgroup (6). However, the combination of pANCA-po-
sitive and ASCA-negative in patients with refractory luminal disease may warrant
further investigation of the values as to predicting a non-response (7). When compa-
red with healthy controls and patients with infectious enterocolitis, the prevalence
of ASCA was significantly increased in patients with Crohn's disease and first-
degree relatives (8). The combination of positive ANCA, negative ASCA and negati-
ve serum agglutinating antibodies to anaerobic coccoid rods, increased the positive
predictive value and specificity in ulcerative colitis. The combination of negative
ANCA and positive ASCA with positive antibodies to coccoid rods increased the po-
sitive predictive value and specificity in Crohn's disease. In this disease, the presen-
ce of positive pANCA was correlated with colonic involvement. No correlation was
found be-tween the presence of any of these three different antibodies and the disea-
se activity, the duration, the behaviour of the inflammation or the response to medi-
cal treatment (9). The role of these antibodies in the pathophysiology of IBD still ne-
eds to be assessed as well as the need to identify the ASCA immunogen(s) that gives
rise to the antibody response (10).
The search for biological markers is not easy. Findings of associations of mar-
kers with sub-groups of patients are influenced by selection bias, recall bias, mis-
classification and confounding. The control of confounding risk factors by study de-
sign or analysis will enhance comparability of studies (11). The effort to embark in
such difficult studies is worthwhile, as Timmer and Sutherland have stated (11),
“the overall prognosis of the disease could be improved through lifestyle changes
and the prediction of relapse may alleviate the psychological burden that constant
fear of incapacitating phases of disease activity poses to the often young and active
patient”.
However, IBD research in association studies on candidate genes has been cha-
racterized by non-replication of results and the inclusion of a limited number of ge-
nes. The vision expressed by Tabor et al. in relation to the candidate-gene approach
in multifactorial diseases is very relevant in IBD. These authors have argued that
the use of epidemiological principles in the selection, analysis and interpretation of
candidate genes and DNA sequence variants should also be applied to candidate-
gene studies. The biological plausibility, the strength of association, the dose-res-
ponse relationship and the consistency are the rules of the game (12). According to
Tabor et al. (12) et al –“the consistency of the association across past and future
studies, and across different populations, is an important consideration. Consistent
replication in different populations is strong evidence of causality. Lack of replica-
Editorial
REV ESP ENFERM DIG 2003; 95(11): 752-754
Vol. 95, N.° 11, 2003 THE VALUE OF SEROLOGICAL AND GENETIC MARKERS IN IBD; STRENGTH AND WEAKNESS OF THE STUDIES 753
tion does not necessarily imply lack of causality, but might point to the need for
more studies in certain populations or more detailed study of the function of a parti-
cular gene”.
It is in this context that we can view the contribution of García Herola and co-
workers in this issue of the journal. The authors recognize that the sample size of
their study is small and the imperfection of the markers. But it is a beginning of the
systematic classification of their patients. The use of good clinical criteria and the
long-term follow-up of the patients with the introduction of new genetic and serolo-
gical markers will contribute to guide treatment decisions and to improve the cost-
benefit relationship.
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